Moreover, as MDS clones harboring splicing factor mutations may be preferentially sensitive to inhibition of the RNA splicing process compared to the unmutated stem/progenitor compartment [30], several drugs targeting the splicing machinery are currently evaluated in clinical trials. This evidence concerns the gene SLU7 and myelodysplastic syndrome.